Cell-permeable ATP-citrate lyase (ACL) inhibitor (IC50 value 0.13 µM in vitro, and 8 µM for inhibition of total lipid syntheses in HepG2 cells). When administered to mice fed on a high-fat diet, it produced an approximate 20–30% lowering in plasma cholesterol and triglycerides, as well as a 30–50% decrease in fasting plasma glucose, as well as an inhibition of weight gain. BMS 303141 also showed inhibitory effects for other metabolic disease related targets such as ACC1 and ACC2 (IC50 values 6 µM and 12 µM, respectively).

KEYWORDS: BMS 303141 | supplier | ACL inhibitor | BMS303141 | CAS [943962-47-8] | ADP | ACL | ATP-citrate lyase | Inhibitor | metabolic disorders | diabetes | obesity | dyslipidemia | acetyl-CoA | fatty acid | cholesterol | cardiovascular | LDL | HDL | weight gain | triglycerides